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Abstract
Background: The study of epigenetic processes and mechanisms present a dynamic approach to assess complex
individual variation in obesity susceptibility. However, few studies have examined epigenetic patterns in preschool-
age children at-risk for obesity despite the relevance of this developmental stage to trajectories of weight gain. We
hypothesized that salivary DNA methylation patterns of key obesogenic genes in Hispanic children would 1)
correlate with maternal BMI and 2) allow for identification of pathways associated with children at-risk for obesity.
Results: Genome-wide DNA methylation was conducted on 92 saliva samples collected from Hispanic preschool
children using the Infinium Illumina HumanMethylation 450 K BeadChip (Illumina, San Diego, CA, USA), which
interrogates >484,000 CpG sites associated with ~24,000 genes. The analysis was limited to 936 genes that have
been associated with obesity in a prior GWAS Study.
Child DNA methylation at 17 CpG sites was found to be significantly associated with maternal BMI, with increased
methylation at 12 CpG sites and decreased methylation at 5 CpG sites. Pathway analysis revealed methylation at
these sites related to homocysteine and methionine degradation as well as cysteine biosynthesis and circadian
rhythm. Furthermore, eight of the 17 CpG sites reside in genes (FSTL1, SORCS2, NRF1, DLC1, PPARGC1B, CHN2, NXPH1)
that have prior known associations with obesity, diabetes, and the insulin pathway.
Conclusions: Our study confirms that saliva is a practical human tissue to obtain in community settings and in
pediatric populations. These salivary findings indicate potential epigenetic differences in Hispanic preschool children
at risk for pediatric obesity. Identifying early biomarkers and understanding pathways that are epigenetically
regulated during this critical stage of child development may present an opportunity for prevention or early
intervention for addressing childhood obesity.
Trial registration: The clinical trial protocol is available at ClinicalTrials.gov (NCT01316653). Registered 3 March 2011
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Background
Prevalence of childhood obesity remains a significant
public health concern, especially in Hispanic populations
who have the higher pediatric obesity rates [1]. Despite
having increased risk of developing pediatric and adult
obesity compared to other ethnic groups [2], Hispanic
children are currently underrepresented in public health
research. This is particularly significant as Hispanics are
the most populous and rapidly growing ethnic minority
in the United States, meaning this population’s health
comorbidities secondary to obesity will increase health-
care costs and rates of morbidity [3, 4]. Genetic predis-
position, exposure to unhealthy dietary options, and lack
of adequate physical activity have all been identified as
contributors to pediatric obesity [5]. However, recent lit-
erature indicates a more nuanced dynamic mechanism
associated with later childhood and adult obesity that re-
flects the interaction between genetics, environment,
and developmental stage via epigenetic modifications
[6–8]. While the study of the epigenome is complex, it
has the potential to inform the prevention and treatment
of pediatric obesity by enhancing our understanding of
timing and the mechanisms by which the genetic code
could be susceptible to environmental influences [9, 10].
Genetic factors are known to affect multiple cellular
and metabolic pathways underlying the development of
obesity such as: adipogenesis and fat storage, adipocyte
accumulation, the hypothalamic-pituitary adrenal (HPA)
system stress response affecting cardiovascular and
metabolic health, gastrointestinal tract regulatory signals,
orexigenic and anorexigenic and satiety mechanisms,
and insulin regulation [11, 12]. For example, there is evi-
dence that adipocyte growth in number and size is
established early, by the age of 2, and is indicative of fu-
ture weight trajectory [13]. Additionally, maternal Body
Mass Index (BMI) is correlated with child’s BMI status
at age 6 [14] and is a better indicator of child’s BMI tra-
jectory than child birth weight alone [6]. Current mater-
nal BMI has been shown to be significantly associated
with current child’s BMI more than other maternal so-
cioeconomic factors (including age, marital status, edu-
cation). These and other studies indicate that both
current and pre-pregnancy maternal BMI are signifi-
cantly associated with child’s BMI trajectory [15, 16].
However, the epigenetic mechanisms affecting po-
tential candidate genes linked to biological processes,
such as adipocyte accumulation, are relatively un-
known in pediatric populations. Epigenetic mecha-
nisms regulate the level of gene transcription, which
occurs through multiple processes including DNA
methylation [8, 17]. Research indicates that methyl
groups can bind the genetic code in either a heritably
stable or an environmentally-induced transient man-
ner, affecting the child’s trajectory for excessive weight
gain relative to height [18, 19]. There is some evi-
dence of in utero environmentally-induced methyla-
tion associated with exposure to maternal gestational
diabetes [20, 21]; maternal inadequate nutrition or in-
sulin resistance that can cause an adaptive response
in the child, resulting in epigenetic modifications sig-
naling caloric retention [22–25]. In addition, Liu and
colleagues reported that maternal pre-pregnancy BMI
was associated with alterations in offspring DNA
methylation in cord blood at CpG sites annotated to
genes related to the development of various complex
chronic diseases, such as cardiovascular disease [9].
While the study by Liu et al. linked maternal weight
phenotypes (normal weight; overweight; and obese) to
epigenetic patterns in offspring neonatal cord blood
samples [9], children between the ages 3–5 have been
relatively understudied in the field of epigenetics. This is
likely due to the convenience of neonatal cord blood at a
younger age and the limited feasibility of obtaining blood
samples until older ages. Yet, this age range is particu-
larly important as it falls closest to the adiposity rebound
stage and could play a significant role in a child’s future
BMI trajectory [26]. Thus, examining the link between
current maternal BMI and young children’s DNA methy-
lation patterns, particularly among Hispanic children at
high risk for obesity, can fill important gaps in current
epigenetic research.
Saliva is a promising yet relatively underutilized source
of DNA [27, 28]. Previous studies indicate that up to
74% of DNA in saliva comes from white blood cells, al-
though there is high variability in individual samples
[29]. Additionally, saliva is part of the gastrointestinal
tract, and therefore, an important tissue to examine in
obesity research [30]. Furthermore, using saliva samples
rather than blood to yield epigenetic information intro-
duces a more practical method to measure epigenetics
from young children in a variety of settings, including
the home and community [31].
While epigenetic patterns are tissue-dependent and
results may not be consistent with other tissues [32],
this study examines if there is variation in salivary
DNA methylation in young children at risk for later
obesity. We had three study aims: 1) to examine the
association of maternal BMI phenotype with methyla-
tion patterns in preschool Hispanic child saliva by
analyzing CpG sites located in genes previously asso-
ciated with obesity [33]; 2) to assess if preschool child
saliva would yield distinct epigenetic signatures in
children at-risk for obesity compared to children of
normal weight mothers; and 3) to identify biological
pathways and genes in children correlated with mater-
nal BMI. These findings could then identify potential
epigenetic signatures in saliva among young children
at risk for obesity, but not yet obese.
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Methods
Ethics statement
The study was approved by the Vanderbilt University
Institutional Review Board (IRB No. 120643). Data
were collected after a parent/legal guardian signed a
written informed consent, for themselves and their
child, in their preferred language (English or Spanish).
The clinical trial protocol is available at ClinicalTrials.gov
(NCT01316653). Registered 3 March 2011. The data for
this manuscript derive from baseline salivary samples ob-
tained prior to randomization.
Sample population study subjects
This study involved baseline saliva samples from 92
Hispanic parent-preschool children dyads, who are
participating in an ongoing randomized controlled
trial (RCT), the Growing Right Onto Wellness
(GROW) Trial [34]. Children were not necessarily
firstborn. Eligibility criteria for the RCT included:
child 3–5 years old; child’s BMI ≥50 and <95% (at
risk for obesity, but not yet obese) [35]; parental
commitment to participate in a 3-year randomized
controlled trial; parent age ≥18 years; parent and
child in good health, without medical conditions ne-
cessitating limited physical activity as evaluated by a
pre-screen; dyad considered underserved as indicated
by the parent self-reporting if they or someone in
their household participated in programs such as
TennCare (Medicaid), CoverKids, Special Supplemental
Nutrition Program for Women, Infants, and Children
(WIC), Food Stamps, and/or free and reduced price
school meal. These children are considered to be at high
risk for later childhood and adult obesity [36].
Phenotypic data
Height and weight were measured in accordance with
standard anthropometric measurement procedures [37,
38]. Both values were collected twice, with the mean of
the two closest measures used as the final measurement.
BMI was calculated as weight in kilograms divided by
the square of height in meters. Table 1 outlines the
phenotypic and demographic data for the sample
population.
Procedures
All salivary samples were collected at baseline in the
GROW RCT, before any interventions occurred, using
the Oragene DNA saliva kit following a strict protocol
[39]. All study members wore gloves and immediately
capped specimen after collection. Samples were sent to
the Vanderbilt genetic core for assessment of quality and
quantity prior to storage in the Vanderbilt Technologies
for Advanced Genomics (VANTAGE) core at Vanderbilt
University. DNA extraction was performed as per DNA
Genotek’s recommendations using the PrepIT L2P re-
agent. Extracted DNA was stored in individually bar-
coded cryovials at −80° Fahrenheit. For children, saliva
was obtained using the “baby brush” approach, in which
small sponges attached to plastic handles are inserted
between cheek and gumline to absorb saliva [40]. The
phenotypic data derived from a baseline survey and ob-
jectively measured anthropomorphic data was collected
from participating mother-child pairs.
Identification of CpG Probes
We focused our analysis on 11,387 CpG sites that re-
sided in 936 genes that have been previously reported in
genome-wide association studies (GWAS) to have asso-
ciation with childhood obesity in a Hispanic population
[41]. Moreover, the original GWAS study’s initial sample
size was 815 Hispanic children from 263 families [41].
Assay method
Genome-wide DNA methylation was conducted on
the 92 saliva samples using the Infinium Illumina
HumanMethylation 450 K BeadChip (Illumina, San
Diego, CA, USA), which interrogates >484,000 CpG
sites associated with ~24,000 genes [42]. This micro-
array spans 99% of genes in the Reference Sequence
database, with an average of 17 CpG sites per gene
region, and has been previously validated for
consistency [43]. Arrays were processed using stand-
ard protocol [44], with three samples randomly se-
lected to serve as duplicates and one sample run with
HapMap DNA to test functionality of reagents. Dupli-
cates were measured for high technique consistency
with Pearson correlation coefficient (>.99).
Table 1 Sample demographics
Child Age, mean (SD) 3.78 (0.78)
Age 3, No. (%) 40 (43)
Age 4, No. (%) 32 (35)
Age 5, No. (%) 20 (22)
Maternal Age, mean (SD) 31.70 (5.75)
Gender, No. (%)
Female 46 (50)
Male 46 (50)
Maternal BMI (kg/m^2), mean (SD) 29.80 (7.60)
Maternal Waist Circumference (cm), mean (SD) 98.16 (16.04)
Child BMI (kg/m^2), mean (SD) 16.80 (0.83)
Child Waist Circumference (cm), mean (SD) 53.34 (3.17)
Child and Parent Race, No. (%)
Hispanic/Hispanic 92 (100)
Oelsner et al. BMC Genomics  (2017) 18:57 Page 3 of 10
Quality control
Methylation data were quality controlled using Illumina
GenomeStudio (V2011.1), Methylation module (V1.9.0).
The data processing and quality control were performed
using the Illumina GenomeStudio, methylation module
1.8. The GenomeStudio had built in protocols for con-
ducting methylation array normalization. We utilized
Background Subtraction, where the background value is
derived by averaging the signals of built-in negative con-
trol bead types. Outliers are removed using the median
absolute deviation method. Background normalization is
capable of minimizing the amount of variation in back-
ground signals between arrays. This is accomplished
using the signals of built-in negative controls, which are
designed to be thermodynamically equivalent to the
regular probes but lack a specific target in the transcrip-
tome. Negative controls allow for estimating the ex-
pected signal level in the absence of hybridization to a
specific target. The average signal of the negative con-
trols is subtracted from the probe signals. As a result,
the expected signal for unexpressed targets is equal to
zero. Samples with lower than 98% call rate (i.e.
<485,000 probes) were excluded.
Any non-specific cross-reacting probes, probes car-
rying common SNPs (MAF >1%), or any probes with
p-values greater than 0.05 for more than 20% of the
sample were sequentially excluded [45, 46]. One saliva
sample was removed after quality control analysis
(total analytic sample of n = 91). Normalization at
CpG island level was performed using internal control
subtracting background noise.
Statistical analysis
We employed an advanced statistical method called elas-
tic net in order to select a reduced set of CpG markers
for regression analyses because the number of CpG
markers is substantially greater than the number of sub-
jects [47]. The elastic net method provides variable se-
lection to produce parsimonious and interpretable
models without being severely limited by the sample size
[47, 48]. While multiple test corrections are not neces-
sary for elastic net [49–51], to demonstrate the more
common presentation of results, we report Hochberg
adjusted p-values [52].
The elastic net was performed prior to linear regres-
sion analysis to identify CpG sites associated with mater-
nal BMI, due to its clinical relevance to childhood
obesity for the Hispanic population [53–55]. The CpG
sites selected by elastic net were then used in a univari-
ate model to examine the individual association with
maternal BMI using a linear regression model where the
main outcome was child CpG methylation and the main
predictor was maternal BMI, adjusting for covariates
that included: child BMI, maternal age, child gender, and
child age.
Pathway analysis
Functional analysis of differentially methylated genes
was conducted using Ingenuity Pathway Analysis (IPA)
on child CpG Sites determined to be significantly meth-
ylated and associated with maternal BMI by linear re-
gression. The analysis utilized the Ingenuity Knowledge
Base (QIAGEN), a structured collection of five million
findings from biomedical literature and integrated third
party databases that contains 40,000 nodes with
1,480,000 edges representing cause-effect relationships.
These cause-and-effect relationships take into account
expression, transcription, activation, molecular modifica-
tion, transport, and binding [56].
Results
Methylation analysis
The elastic net identified 17 CpG sites that were associ-
ated with maternal BMI (Fig. 1). Twelve of the 17 CpGs
had increased methylation with increased maternal BMI
while 5 of the 17 CpGs had decreased methylation asso-
ciated with increased maternal BMI. Of these CpGs, all
were significantly and independently associated with ma-
ternal BMI, as determined by linear regression (Table 2).
Five CpGs were found within an enhancer region of the
associated gene, 1 CpG was associated with the promo-
tor region, and 5 CpGs were unclassified.
Pathway analysis
The top 10 canonical signaling pathways included cyst-
eine biosynthesis, homocysteine degradation, cysteine
biosynthesesis III, superpathway of methionine degrad-
ation, D-glucuronate degradation I, and Circadium
Rhythm Signaling (Table 3).
Discussion
To our knowledge, this is the first study examining
DNA methylation in saliva samples obtained from
preschool-age Hispanic children to investigate epigenetic
patterns in children at-risk for later childhood obesity.
We identified 17 CpG sites in saliva of children to be as-
sociated with maternal BMI, indicating a potential inter-
generational transmission of risk for obesity in children
of obese mothers.
Effect of maternal BMI phenotype on child DNA
methylation in saliva
The 17 CpG probes identified by the Elastic net analysis
from saliva samples are consistent with Comuzzie et al’s
original GWAS study of whole blood DNA samples from
815 Hispanic children in 263 families [41]. The 17 CpG
sites in Table 2 were independently and significantly
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Fig. 1 Direct Correlation of CpG Site with Maternal Obesity. Maternal BMI per Child methylation level for the 17 CpG sites with significant
methylation as determined by linear regression. Genes indicated in parenthesis; Red line indicating linear regression; dotted line indicating 95%
confidence interval
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associated with maternal BMI. While child age was con-
trolled for in the linear regression analysis, these patterns
may change as children age. We plan to assess epigenetic
signatures and the development of childhood obesity over
time in future research.
Top differentially methylated genes
Eight out of the 17 CpG sites selected by the elastic net
analysis reside in genes that are associated with obesity,
diabetes, or the insulin pathway by prior studies
(Table 2). Specifically, the PPARGC1B and NXPH1
genes have been associated with childhood obesity in
Brazil and with diabetes in the Mexican-Mestizo popula-
tions respectively. Since our population was solely His-
panic, we found it interesting that the saliva epigenetic
signatures were consistent with known genetic causes of
obesity and diabetes in similar populations of Hispanic
origins. There are similarities between obesogenic and
oncogenic states, namely cellular proliferation and in-
flammation, and it is interesting to note, that in this
study two of the genes with significant methylation,
DLC1 and CRYL1, are associated with hepatocellular
carcinoma. These genes have biologic plausibility of con-
tributing to an increased risk of childhood obesity. How-
ever, because the saliva samples were derived from
children within similar non-obese BMI ranges, these sig-
nificant differences may indicate changes occurring in
numerous different pathways even before the clinical
presentation of obesity.
Table 2 Linear regression analysis of child DNA methylation signal predicted by maternal BMI
Probe Gene Effect Standard Deviation P-Value* Associated Pathology
cg21790991a FSTL1 0.005058 0.001776 0.0156 Obesity [65, 66]
Cg03218460 SORCS2 0.003025 0.001091 0.0165 Cardiovascular disease [67]
SORCS family associated with Type 1
and 2 Diabetes [67–70]
Cg23241637 ZNF804A 0.002443 0.00081 0.0143 Schizophrenia [71–75]
Cg04798490 SHANK2 0.002391 0.000787 0.0143 Autism [76–81]
cg01307483 NRF1 0.002344 0.000879 0.0172 Type 2 Diabetes [82–85]
cg19312314 CBS 0.001952 0.000813 0.0243 Cardiovascular Disease [86]
Homocystinuria [87–89]
cg14321859 DLC1 0.001801 0.00076 0.0243 Insulin-Pathway [90]
Hepatocellular Carcinoma [91–94]
cg03067613 ATP8B3 0.001547 0.000672 0.0253 Reproduction [95, 96]
Liver Disease [97]
cg11296553 CEP72 0.001159 0.000312 0.0041 Ulcerative colitis [86]
cg16509445 CRYL1 0.001091 0.000427 0.0204 Hepatocellular Carcinoma [98, 99]
Cg16344026 PPARGC1B 0.001021 0.000403 0.0204 Obesity [100–102]
Cg15354625 ODZ4 0.000932 0.000402 0.0253 Bipolar Disorder [103–105]
cg23836542 CHN2 −0.00081 0.000337 0.0243 Insulin-Pathway [106]
Type 2 Diabetes [107, 108]
cg07511564 NXPH1 −0.00135 0.00061 0.0295 Type 2 Diabetes [109, 110]
cg18799510 GRIN3A −0.00171 0.000633 0.0172 Schizophrenia [111, 112]
Cg14996807 UNC13A −0.00174 0.00048 0.0041 Amyotrophic lateral sclerosis [113–116]
Cg18431297 SORCS2 −0.00316 0.001079 0.0146 Cardiovascular disease [67]
SORCS family associated with Type 1
and 2 Diabetes [67–70]
*Hochberg adjusted p-values noted
aBolded CpG sites are associated with Obesity, Diabetes, and/or the Insulin-Pathway
Table 3 Top 10 signaling pathways derived from top
differentially methylated genes
Top Canonical Pathways
Adjusted P-value
Cysteine Biosynthesis/Homocysteine Degradation 1.55E-03
D-glucuronate Degradation I 2.33E-03
Cysteine Biosynthesis III (Mammalia) 1.46E-02
Superpathway of Methionine Degradation 2.45E-02
Circadian Rhythm Signaling 2.53E-02
Top Diseases and Bio Functions
Developmental Disorders (3 Molecules) 4.70E-02 - 7.76E-04 3
Hematological Disease (6 Molecules) 3.98E-02 - 7.76E-04 6
Hereditary Disorder (5 Molecules) 4.70E-02 - 7.76E-04 5
Metabolic Disease (5 Molecules) 3.96E-02 - 7.76E-04 5
Neurological Disease (8 Molecules) 4.41E-02 - 7.76E-04
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One unexpected finding, was that 5 of the 17 CpG
sites with significant methylation have strong associa-
tions with neurological disease in the literature, specific-
ally schizophrenia, bipolar disorder, autism, and
amyotrophic lateral sclerosis (Table 2) [57, 58].
Pathway analysis
Pathway analysis identified significant enrichment of
genes within pathways involved in conical signaling with
respect to methylation in cysteine biosynthesis, homo-
cysteine degradation, cysteine biosynthesis III, and me-
thionine degradation pathways (Table 3). These
pathways have been associated with obesity previously.
For example, cysteine biosynthesis has been found to be
positively associated with risk of obesity in Hispanic
children [59], and total plasma cysteine has been inde-
pendently associated with obesity and insulin resistance
in the same population [60]. Furthermore, homocysteine
degradation has been found to be positively associated
with morbidly obese patients [61], and restriction of me-
thionine intake has been shown to have a significant in-
crease in fat oxidation [62]. Circadian rhythm was also
identified as a top canonical pathway. Circadian rhythms
regulate many biological processes and cellular meta-
bolic pathways. Disruption of circadian rhythm has an
adverse effect on metabolic function [63].
Salivary vs blood assays
Comuzzie et al. used DNA samples from whole blood in
a GWAS study to identify novel genetic loci associated
with the pathophysiology of childhood obesity in His-
panic children ages 4–19 years old [41]. Using these
same genes in our analyses of saliva, we identified 17
CpG sites in a Hispanic pediatric population with signifi-
cant methylation and associated with maternal obeso-
genic phenotypes. Thus, this proof of principle study
demonstrated that saliva is a probable viable medium for
epigenetic testing, which in this case, was consistent to
whole blood findings, but we acknowledge that further
testing would have to include both blood and saliva sam-
ples from the same Hispanic pediatric population to hol-
istically assess the similarities between these 2 tissue
samples. Previous studies that have investigated both of
these tissues in other patient populations indicate that
saliva and whole blood findings are consistent, so we
would anticipate further investigations to yield similar
findings [25, 26].
Limitations
Although prior literature indicates that DNA methyla-
tion levels in saliva are similar to those in peripheral
blood, skin fibroblasts, and buccal swab DNA, it may
not reflect the epigenome of adipose tissue, muscle, pan-
creas, GI system, and pituitary [64], which are implicated
in the development of obesity. Furthermore, we acknow-
ledge that we cannot assess whether these findings
would be consistent in blood samples in this specific
population, although prior literature seems to indicate
that we would find similar epigenetic methylation pat-
terns if tested. We did not correlate gene expression
data with methylation changes, and thus can only
speculate on the implications for a child’s BMI trajec-
tory. P-adjusted values were less likely to be signifi-
cant due to the large number of genes analyzed in
the Illumina Human Methylation Bead Chip 450 K,
making our statistically significant findings important,
but likely under-identifying other potential statistically
significant differential methylation patterns.
Conclusions
Results of this proof of principle study indicate that sal-
iva is a practical way to obtain biologically plausible find-
ings in an epigenetic analysis of preschool-age children.
It is important to understand the potential pathways that
could be epigenetically regulated in preschool aged chil-
dren who are not currently obese but at higher risk of
obesity. Moreover, saliva, an easily accessible tissue,
could assist in the future identification of early bio-
markers of later childhood obesity and metabolic dys-
function, presenting an opportunity for prevention or
early intervention for addressing childhood obesity.
Abbreviations
BMI: Body Mass Index; GROW: The Growing Right Onto Wellness Trial;
GWAS: Genome-wide Association Studies; HPA: Hypothalamic-Pituitary
Adrenal; RCT: Randomized Controlled Trial; VANTAGE: the Vanderbilt
Technologies for Advanced Genomics; WIC: The Special Supplemental
Nutrition Program for Women, Infants, and Children
Acknowledgements
We are grateful for the participation of the Hispanic families involved in this
study.
Funding
This research was supported by grants (U01 HL103620) with additional
support for the remaining members of the COPTR Consortium
(U01HL103622, U01HL103561, U01HD068890, U01HL103629) from the
National Heart, Lung, and Blood Institute and the Eunice Kennedy Shriver
National Institute of Child Health and Development and the Office of
Behavioral and Social Sciences Research. The content is solely the
responsibility of the authors and does not necessarily represent the official
views of the National Heart, Lung, And Blood Institute, the National Institutes
of Health, or the National Institute of Child Health and Development. This
research was also supported by grants 5P30DK092986-03 from the National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and
5UL1TR0045 from the Vanderbilt Institute for Clinical and Translational
Research (VICTR).
Availability of data and materials
The datasets supporting the conclusions of this article are available in NCBI’s
Gene Expression Omnibus and are accessible through GEO Series access
number GSE72556 (https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE72556).
Oelsner et al. BMC Genomics  (2017) 18:57 Page 7 of 10
Authors’ contribution
Conceived and designed the experiments: SB and KT. Analyzed the data: YG.
Wrote the paper: SB, KT, AN, ST. Edited and proofed the paper: all authors. All
authors read and approved the final manuascript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Data were collected after informed consent was obtained by parent/legal
guardian. This study was approved by the Vanderbilt University Institutional
Review Board (IRB No. 120643).
Author details
1College of Medicine, Medical University of South Carolina, 96 Jonathan
Lucas St, Suite 601, MSC 617, Charleston, SC 29425, USA. 2Center for
Quantitative Research, School of Medicine, Vanderbilt University, 2220 Pierce
Ave, 571 Preston Research Building, Nashville, TN, USA. 3Department of
Biological Sciences, Vanderbilt University, 1210 BSB, 465 21st Ave S, Nashville,
TN, USA. 4Department of Anthropology, University of California San Diego,
9500 Gilman Drive, La Jolla, CA 92093, USA. 5Department of Pediatrics,
Vanderbilt University School of Medicine, 2200 Children’s Way, Doctor’s
Office Tower 8232, Nashville, TN 37232-9225, USA. 6Pediatric Obesity
Research, Diabetes Research and Training Center, Vanderbilt University
School of Medicine, 2200 Children’s Way, Doctor’s Office Tower 8232,
Nashville, TN 37232-9225, USA.
Received: 11 February 2016 Accepted: 26 December 2016
References
1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in
body mass index among US children and adolescents, 1999–2010. JAMA.
2012;307:483–90.
2. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult
obesity in the United States, 2011–2012. JAMA. 2014;311:806–14.
3. Ramirez A, Gallion K, Despres C. Latino Childhood Obesity. In: Brennan VM,
Kumanyika SK, Zambrana RE, editors. Obesity Interventions in Underserved
Communities: Evidence and Directions. Baltimore: The Johns Hopkins
University Press; 2014. p. 43–62.
4. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM.
Prevalence of overweight and obesity among US children, adolescents, and
adults, 1999-2002. JAMA. 2004;291(23):2847–50. doi:10.1001/jama.291.23.
2847.
5. May AL, Pan L, Sherry B, Blanck HM, Galuska D, Dalenius K, Polhamus B,
Kettel-Khan L, Grummer-Strawn LM. Vital signs: obesity among low-income,
preschool-aged children–United States, 2008–2011. MMWR Morb Mortal
Wkly Rep. 2013;62:629–34.
6. Parsons TJ, Power C, Manor O. Fetal and early life growth and body mass
index from birth to early adulthood in 1958 British cohort: longitudinal
study. BMJ. 2001;323:1331–5.
7. Grissom NM, Reyes TM. Gestational overgrowth and undergrowth affect
neurodevelopment: similarities and differences from behavior to
epigenetics. Int J Dev Neurosci. 2013;31:406–14.
8. Miller GE, Chen E, Parker KJ. Psychological stress in childhood and
susceptibility to the chronic diseases of aging: moving toward a model of
behavioral and biological mechanisms. Psychol Bull. 2011;137:959–97.
9. Liu X, Chen Q, Tsai HJ, Wang G, Hong X, Zhou Y, et al. Maternal
preconception body mass index and offspring cord blood DNA
methylation: exploration of early life origins of disease. Environ Mol
Mutagen. 2014;55:223–30.
10. Dubois L, Ohm Kyvik K, Girard M, Tatone-Tokuda F, Perusse D, Hjelmborg J,
et al. Genetic and environmental contributions to weight, height, and BMI
from birth to 19 years of age: an international study of over 12,000 twin
pairs. PLoS One. 2012;7:e30153.
11. Breton C. The hypothalamus-adipose axis is a key target of developmental
programming by maternal nutritional manipulation. J Endocrinol. 2013;216:
R19–31.
12. Bouchard L, Rabasa-Lhoret R, Faraj M, Lavoie ME, Mill J, Perusse L, et al.
Differential epigenomic and transcriptomic responses in subcutaneous
adipose tissue between low and high responders to caloric restriction. Am J
Clin Nutr. 2010;91:309–20.
13. Knittle JL, Timmers K, Ginsberg-Fellner F, Brown RE, Katz DP. The
growth of adipose tissue in children and adolescents. Cross-sectional
and longitudinal studies of adipose cell number and size. J Clin Invest.
1979;63:239–46.
14. Brune BC, Gerlach MK, Seewald MJ, Brune TG. Early postnatal BMI
adaptation is regulated during a fixed time period and mainly depends on
maternal BMI. Obesity (Silver Spring). 2010;18:798–802.
15. Barroso CS, Roncancio A, Hinojosa MB, Reifsnider E. The association
between early childhood overweight and maternal factors. Child Obes.
2012;8:449–54.
16. Mamun AA, O'Callaghan MJ, Williams GM, Najman JM. Change in maternal
body mass index is associated with offspring body mass index: a 21-year
prospective study. Eur J Nutr. 2013;52:1597–606.
17. Feinberg AP. Epigenetics at the epicenter of modern medicine. JAMA. 2008;
299:1345–50.
18. Fraga MF, Ballestar E, Paz MF, Ropero S, Setien F, Ballestar ML, et al.
Epigenetic differences arise during the lifetime of monozygotic twins. Proc
Natl Acad Sci U S A. 2005;102:10604–9.
19. Herrera BM, Keildson S, Lindgren CM. Genetics and epigenetics of obesity.
Maturitas. 2011;69:41–9.
20. Hillier TA, Pedula KL, Schmidt MM, Mullen JA, Charles MA, Pettitt DJ.
Childhood obesity and metabolic imprinting: the ongoing effects of
maternal hyperglycemia. Diabetes Care. 2007;30:2287–92.
21. Ornoy A. Growth and neurodevelopmental outcome of children born to
mothers with pregestational and gestational diabetes. Pediatr Endocrinol
Rev. 2005;3:104–13.
22. Godfrey KM, Sheppard A, Gluckman PD, Lillycrop KA, Burdge GC, McLean C,
et al. Epigenetic gene promoter methylation at birth is associated with
child's later adiposity. Diabetes. 2011;60:1528–34.
23. Heijmans BT, Tobi EW, Stein AD, Putter H, Blauw GJ, Susser ES, et al.
Persistent epigenetic differences associated with prenatal exposure to
famine in humans. Proc Natl Acad Sci U S A. 2008;105:17046–9.
24. Hochberg Z, Feil R, Constancia M, Fraga M, Junien C, Carel JC, et al. Child
health, developmental plasticity, and epigenetic programming. Endocr Rev.
2011;32:159–224.
25. Sorensen HT, Sabroe S, Rothman KJ, Gillman M, Fischer P, Sorensen TI.
Relation between weight and length at birth and body mass index in
young adulthood: cohort study. BMJ. 1997;315:1137.
26. Whitaker RC, Pepe MS, Wright JA, Seidel KD, Dietz WH. Early adiposity
rebound and the risk of adult obesity. Pediatrics. 1998;101:E5.
27. Thompson TM, Sharfi D, Lee M, Yrigollen CM, Naumova OY, Grigorenko EL.
Comparison of whole-genome DNA methylation patterns in whole blood,
saliva, and lymphoblastoid cell lines. Behav Genet. 2013;43:168–76.
28. Abraham JE, Maranian MJ, Spiteri I, Russell R, Ingle S, Luccarini C, et al. Saliva
samples are a viable alternative to blood samples as a source of DNA for
high throughput genotyping. BMC Med Genomics. 2012;5:19.
29. Thiede C, Prange-Krex G, Freiberg-Richter J, Bornhauser M, Ehninger G.
Buccal swabs but not mouthwash samples can be used to obtain
pretransplant DNA fingerprints from recipients of allogeneic bone marrow
transplants. Bone Marrow Transplant. 2000;25:575–7.
30. Segata N, Haake SK, Mannon P, Lemon KP, Waldron L, Gevers D, et al.
Composition of the adult digestive tract bacterial microbiome based on
seven mouth surfaces, tonsils, throat and stool samples. Genome Biol. 2012;
13:R42.
31. Wu HC, Wang Q, Chung WK, Andrulis IL, Daly MB, John EM, et al.
Correlation of DNA methylation levels in blood and saliva DNA in young
girls of the LEGACY Girls study. Epigenetics. 2014;9:929–33.
32. Wang D, Liu X, Zhou Y, Xie H, Hong X, Tsai HJ, et al. Individual variation and
longitudinal pattern of genome-wide DNA methylation from birth to the
first two years of life. Epigenetics. 2012;7:594–605.
33. Hindorff LA MJ, Morales J, Junkins HA, Hall PN, Klemm AK, and Manolio TA.
A Catalog of Published Genome-Wide Association Studies. Available at:
www.genome.gov/gwastudies. Accessed 6 Dec 2015.
34. Po’e EK, Heerman WJ, Mistry RS, Barkin SL. Growing Right Onto Wellness
(GROW): a family-centered, community-based obesity prevention
randomized controlled trial for preschool child–parent pairs. Contemp Clin
Trials. 2013;36:436–49.
Oelsner et al. BMC Genomics  (2017) 18:57 Page 8 of 10
35. National Center for Health Statistics and the National Center for Chronic
Disease Prevention and Health Promotion. 2000 CDC Growth Charts for the
United States: Methods and Development. 2002;11:246.
36. Pryor LE, Tremblay RE, Boivin M, Touchette E, Dubois L, Genolini C, et al.
Developmental trajectories of body mass index in early childhood and their
risk factors: an 8-year longitudinal study. Arch Pediatr Adolesc Med. 2011;
165:906–12.
37. Barkin SL, Gesell SB, Po’e EK, Escarfuller J, Tempesti T. Culturally Tailored,
Family-Centered, Behavioral Obesity Intervention for Latino-American
Preschool-aged Children. Pediatrics. 2012;130:445–56.
38. Robinson TN, Matheson DM, Kraemer HC, Wilson DM, Obarzanek E, Thompson
NS, et al. A Randomized Controlled Trial of Culturally Tailored Dance and
Reducing Screen Time to Prevent Weight Gain in Low-Income African
American Girls: Stanford GEMS. Arch Pediatr Adolesc Med. 2010;164:995–1004.
39. Nunes AP, Oliveira IO, Santos BR, Millech C, Silva LP, Gonzalez DA, et al.
Quality of DNA extracted from saliva samples collected with the Oragene
DNA self-collection kit. BMC Med Res Methodol. 2012;12:65.
40. Ng DP, Koh D, Choo S, Chia KS. Saliva as a viable alternative source of
human genomic DNA in genetic epidemiology. Clin Chim Acta. 2006;367:
81–5.
41. Comuzzie AG, Cole SA, Laston SL, Voruganti VS, Haack K, Gibbs RA, et al.
Novel genetic loci identified for the pathophysiology of childhood obesity
in the Hispanic population. PLoS One. 2012;7:e51954.
42. Illumina Inc. Infinium HumanMethylation450 BeadChip Kit. 2015
43. Sandoval J, Heyn H, Moran S, Serra-Musach J, Pujana MA, Bibikova M, et al.
Validation of a DNA methylation microarray for 450,000 CpG sites in the
human genome. Epigenetics. 2011;6:692–702.
44. Bibikova M, Fan JB. GoldenGate assay for DNA methylation profiling.
Methods Mol Biol. 2009;507:149–63.
45. Dedeurwaerder S, Defrance M, Bizet M, Calonne E, Bontempi G, Fuks F. A
comprehensive overview of Infinium HumanMethylation450 data
processing. Brief Bioinform. 2014;15:929–41.
46. Chen YA, Lemire M, Choufani S, Butcher DT, Grafodatskaya D, Zanke BW, et
al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina
Infinium HumanMethylation450 microarray. Epigenetics. 2013;8:203–9.
47. Zou H, Hastie T. Regularization and variable selection via the elastic net.
J Roy Stat Soc B. 2005;67:768.
48. Anjum S, Fourkala EO, Zikan M, Wong A, Gentry-Maharaj A, Jones A, et al. A
BRCA1-mutation associated DNA methylation signature in blood cells predicts
sporadic breast cancer incidence and survival. Genome Med. 2014;6:47.
49. Schmutz M, Zucknick M, Schlenk RF, Döhner K, Döhner H, Plass C, et al.
Differential DNA Methylation Predicts Response To Combined Treatment
Regimens With a DNA Methyltransferase Inhibitor In Acute Myeloid
Leukemia (AML). Blood. 2013;122:2539.
50. Wilhelm-Benartzi CS, Koestler DC, Karagas MR, Flanagan JM, Christensen BC,
Kelsey KT, et al. Review of processing and analysis methods for DNA
methylation array data. Br J Cancer. 2013;109:1394–402.
51. Horvath S. DNA methylation age of human tissues and cell types. Genome
Biol. 2013;14:R115.
52. Hochberg Y. A sharper Bonferroni procedure for multiple tests of
significance. Biometricka. 1988;75:800–2.
53. Zhu S, Heymsfield SB, Toyoshima H, Wang Z, Pietrobelli A, Heshka S. Race-
ethnicity-specific waist circumference cutoffs for identifying cardiovascular
disease risk factors. Am J Clin Nutr. 2005;81:409–15.
54. Colin Bell A, Adair LS, Popkin BM. Ethnic differences in the association
between body mass index and hypertension. Am J Epidemiol. 2002;155:
346–53.
55. Misra A, Wasir JS, Vikram NK. Waist circumference criteria for the diagnosis
of abdominal obesity are not applicable uniformly to all populations and
ethnic groups. Nutrition. 2005;21:969–76.
56. Kramer A, Green J, Pollard Jr J, Tugendreich S. Causal analysis approaches in
Ingenuity Pathway Analysis. Bioinformatics. 2014;30:523–30.
57. Jo H, Schieve LA, Sharma AJ, Hinkle SN, Li R, Lind JN. Maternal
prepregnancy body mass index and child psychosocial development at
6 years of age. Pediatrics. 2015;135:e1198–1209.
58. Manu P, Dima L, Shulman M, Vancampfort D, De Hert M, Correll CU. Weight
gain and obesity in schizophrenia: epidemiology, pathobiology, and
management. Acta Psychiatr Scand. 2015;132:97–108.
59. Elshorbagy AK, Kozich V, Smith AD, Refsum H. Cysteine and obesity:
consistency of the evidence across epidemiologic, animal and cellular
studies. Curr Opin Clin Nutr Metab Care. 2012;15:49–57.
60. Elshorbagy AK, Valdivia-Garcia M, Refsum H, Butte N. The association of
cysteine with obesity, inflammatory cytokines and insulin resistance in
Hispanic children and adolescents. PLoS One. 2012;7:e44166.
61. Vaya A, Rivera L, Hernandez-Mijares A, de la Fuente M, Sola E, Romagnoli M,
et al. Homocysteine levels in morbidly obese patients: its association with
waist circumference and insulin resistance. Clin Hemorheol Microcirc. 2012;
52:49–56.
62. Plaisance EP, Greenway FL, Boudreau A, Hill KL, Johnson WD, Krajcik RA, et
al. Dietary methionine restriction increases fat oxidation in obese adults
with metabolic syndrome. J Clin Endocrinol Metab. 2011;96:E836–840.
63. Yoshino J, Klein S. A novel link between circadian clocks and adipose tissue
energy metabolism. Diabetes. 2013;62:2175–7.
64. Souren NY, Tierling S, Fryns JP, Derom C, Walter J, Zeegers MP. DNA
methylation variability at growth-related imprints does not contribute to
overweight in monozygotic twins discordant for BMI. Obesity (Silver Spring).
2011;19:1519–22.
65. Wu Y, Zhou S, Smas CM. Downregulated expression of the secreted
glycoprotein follistatin-like 1 (Fstl1) is a robust hallmark of preadipocyte to
adipocyte conversion. Mech Dev. 2010;127:183–202.
66. Fan N, Sun H, Wang Y, Zhang L, Xia Z, Peng L, et al. Follistatin-like 1: a
potential mediator of inflammation in obesity. Mediators Inflamm. 2013;
2013:752519.
67. Schmidt V, Willnow TE. Protein sorting gone wrong - VPS10P domain
receptors in cardiovascular and metabolic diseases. Atherosclerosis. 2016;
245:194–9.
68. Goodarzi MO, Lehman DM, Taylor KD, Guo X, Cui J, Quinones MJ, et al.
SORCS1: a novel human type 2 diabetes susceptibility gene suggested by
the mouse. Diabetes. 2007;56:1922–9.
69. Paterson AD, Waggott D, Boright AP, Hosseini SM, Shen E, Sylvestre MP, et
al. A genome-wide association study identifies a novel major locus for
glycemic control in type 1 diabetes, as measured by both A1C and glucose.
Diabetes. 2010;59:539–49.
70. Granhall C, Park HB, Fakhrai-Rad H, Luthman H. High-resolution quantitative
trait locus analysis reveals multiple diabetes susceptibility loci mapped to
intervals < 800 kb in the species-conserved Niddm1i of the GK rat. Genetics.
2006;174:1565–72.
71. Donohoe G, Morris DW, Corvin A. The psychosis susceptibility gene
ZNF804A: associations, functions, and phenotypes. Schizophr Bull. 2010;36:
904–9.
72. Girgenti MJ, LoTurco JJ, Maher BJ. ZNF804a regulates expression of the
schizophrenia-associated genes PRSS16, COMT, PDE4B, and DRD2. PLoS
One. 2012;7:e32404.
73. Balog Z, Kiss I, Keri S. ZNF804A may be associated with executive control of
attention. Genes Brain Behav. 2011;10:223–7.
74. Donohoe G, Rose E, Frodl T, Morris D, Spoletini I, Adriano F, et al. ZNF804A
risk allele is associated with relatively intact gray matter volume in patients
with schizophrenia. Neuroimage. 2011;54:2132–7.
75. Lencz T, Szeszko PR, DeRosse P, Burdick KE, Bromet EJ, Bilder RM, et al. A
schizophrenia risk gene, ZNF804A, influences neuroanatomical and
neurocognitive phenotypes. Neuropsychopharmacology. 2010;35:2284–91.
76. Berkel S, Marshall CR, Weiss B, Howe J, Roeth R, Moog U, et al. Mutations in
the SHANK2 synaptic scaffolding gene in autism spectrum disorder and
mental retardation. Nat Genet. 2010;42:489–91.
77. Berkel S, Tang W, Trevino M, Vogt M, Obenhaus HA, Gass P, et al. Inherited
and de novo SHANK2 variants associated with autism spectrum disorder
impair neuronal morphogenesis and physiology. Hum Mol Genet. 2012;21:
344–57.
78. Kumar RA. SHANK2 redemption: another synaptic protein for mental
retardation and autism. Clin Genet. 2010;78:519–21.
79. Won H, Lee HR, Gee HY, Mah W, Kim JI, Lee J, et al. Autistic-like social
behaviour in Shank2-mutant mice improved by restoring NMDA receptor
function. Nature. 2012;486:261–5.
80. Leblond CS, Heinrich J, Delorme R, Proepper C, Betancur C, Huguet G,
et al. Genetic and functional analyses of SHANK2 mutations suggest a
multiple hit model of autism spectrum disorders. PLoS Genet. 2012;8:
e1002521.
81. Tse MT. Neurodevelopmental disorders: exploring the links between
SHANK2 and autism. Nat Rev Drug Discov. 2012;11:518.
82. Liu Y, Niu N, Zhu X, Du T, Wang X, Chen D, et al. Genetic variation and
association analyses of the nuclear respiratory factor 1 (nRF1) gene in
Chinese patients with type 2 diabetes. Diabetes. 2008;57:777–82.
Oelsner et al. BMC Genomics  (2017) 18:57 Page 9 of 10
83. Qu L, He B, Pan Y, Xu Y, Zhu C, Tang Z, et al. Association between
polymorphisms in RAPGEF1, TP53, NRF1 and type 2 diabetes in Chinese
Han population. Diabetes Res Clin Pract. 2011;91:171–6.
84. van Tienen FH, Lindsey PJ, van der Kallen CJ, Smeets HJ. Prolonged Nrf1
overexpression triggers adipocyte inflammation and insulin resistance. J Cell
Biochem. 2010;111:1575–85.
85. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, et al.
Coordinated reduction of genes of oxidative metabolism in humans with
insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl
Acad Sci U S A. 2003;100:8466–71.
86. McGovern DP, Gardet A, Torkvist L, Goyette P, Essers J, Taylor KD, et al.
Genome-wide association identifies multiple ulcerative colitis susceptibility
loci. Nat Genet. 2010;42:332–7.
87. Sabin MA, Werther GA, Kiess W. Genetics of obesity and overgrowth
syndromes. Best Pract Res Clin Endocrinol Metab. 2011;25:207–20.
88. Ignoul S, Eggermont J. CBS domains: structure, function, and pathology in
human proteins. Am J Physiol Cell Physiol. 2005;289:C1369–1378.
89. Picker JD, Levy HL. Homocystinuria Caused by Cystathionine Beta-Synthase
Deficiency. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A,
Bean LJH, et al., editors. GeneReviews(R). Seattle (WA) 1993.
90. Liao YC, Lo SH. Deleted in liver cancer-1 (DLC-1): a tumor suppressor not
just for liver. Int J Biochem Cell Biol. 2008;40:843–7.
91. Xue W, Krasnitz A, Lucito R, Sordella R, Vanaelst L, Cordon-Cardo C, et al.
DLC1 is a chromosome 8p tumor suppressor whose loss promotes
hepatocellular carcinoma. Genes Dev. 2008;22:1439–44.
92. Wong CC, Wong CM, Ko FC, Chan LK, Ching YP, Yam JW, et al. Deleted in
liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in
hepatocellular carcinoma. PLoS One. 2008;3:e2779.
93. Wong CM, Yam JW, Ching YP, Yau TO, Leung TH, Jin DY, et al. Rho GTPase-
activating protein deleted in liver cancer suppresses cell proliferation and
invasion in hepatocellular carcinoma. Cancer Res. 2005;65:8861–8.
94. Tripathi V, Popescu NC, Zimonjic DB. DLC1 interaction with alpha-catenin
stabilizes adherens junctions and enhances DLC1 antioncogenic activity.
Mol Cell Biol. 2012;32:2145–59.
95. Gong EY, Park E, Lee HJ, Lee K. Expression of Atp8b3 in murine testis and its
characterization as a testis specific P-type ATPase. Reproduction. 2009;137:345–51.
96. Folmer DE, Elferink RP, Paulusma CC. P4 ATPases - lipid flippases and their
role in disease. Biochim Biophys Acta. 2009;1791:628–35.
97. Harris MJ, Arias IM. FIC1, a P-type ATPase linked to cholestatic liver disease,
has homologues (ATP8B2 and ATP8B3) expressed throughout the body.
Biochim Biophys Acta. 2003;1633:127–31.
98. Cheng IK, Ching AK, Chan TC, Chan AW, Wong CK, Choy KW, et al. Reduced
CRYL1 expression in hepatocellular carcinoma confers cell growth
advantages and correlates with adverse patient prognosis. J Pathol. 2010;
220:348–60.
99. Chen CF, Yeh SH, Chen DS, Chen PJ, Jou YS. Molecular genetic evidence
supporting a novel human hepatocellular carcinoma tumor suppressor
locus at 13q12.11. Genes Chromosomes Cancer. 2005;44:320–8.
100. Park KS, Shin HD, Park BL, Cheong HS, Cho YM, Lee HK, et al. Putative
association of peroxisome proliferator-activated receptor gamma co-
activator 1beta (PPARGC1B) polymorphism with Type 2 diabetes mellitus.
Diabet Med. 2006;23:635–42.
101. Andersen G, Wegner L, Yanagisawa K, Rose CS, Lin J, Glumer C, et al.
Evidence of an association between genetic variation of the coactivator
PGC-1beta and obesity. J Med Genet. 2005;42:402–7.
102. Queiroz EM, Candido AP, Castro IM, Bastos AQ, Machado-Coelho GL, Freitas
RN. IGF2, LEPR, POMC, PPARG, and PPARGC1 gene variants are associated
with obesity-related risk phenotypes in Brazilian children and adolescents.
Braz J Med Biol Res. 2015;48:595–602.
103. Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale
genome-wide association analysis of bipolar disorder identifies a new
susceptibility locus near ODZ4. Nat Genet. 2011;43:977–83.
104. Heinrich A, Lourdusamy A, Tzschoppe J, Vollstadt-Klein S, Buhler M, Steiner
S, et al. The risk variant in ODZ4 for bipolar disorder impacts on amygdala
activation during reward processing. Bipolar Disord. 2013;15:440–5.
105. Craddock N, Sklar P. Genetics of bipolar disorder. Lancet. 2013;381:1654–62.
106. Suliman SG, Stanik J, McCulloch LJ, Wilson N, Edghill EL, Misovicova N, et al.
Severe insulin resistance and intrauterine growth deficiency associated with
haploinsufficiency for INSR and CHN2: new insights into synergistic
pathways involved in growth and metabolism. Diabetes. 2009;58:2954–61.
107. Maeda S, Araki S, Babazono T, Toyoda M, Umezono T, Kawai K, et al.
Replication study for the association between four Loci identified by a
genome-wide association study on European American subjects with type
1 diabetes and susceptibility to diabetic nephropathy in Japanese subjects
with type 2 diabetes. Diabetes. 2010;59:2075–9.
108. Hu C, Zhang R, Yu W, Wang J, Wang C, Pang C, et al. CPVL/CHN2 genetic
variant is associated with diabetic retinopathy in Chinese type 2 diabetic
patients. Diabetes. 2011;60:3085–9.
109. Gamboa-Melendez MA, Huerta-Chagoya A, Moreno-Macias H, Vazquez-
Cardenas P, Ordonez-Sanchez ML, Rodriguez-Guillen R, et al. Contribution of
common genetic variation to the risk of type 2 diabetes in the Mexican
Mestizo population. Diabetes. 2012;61:3314–21.
110. Hayes MG, Pluzhnikov A, Miyake K, Sun Y, Ng MC, Roe CA, et al.
Identification of type 2 diabetes genes in Mexican Americans through
genome-wide association studies. Diabetes. 2007;56:3033–44.
111. Takata A, Iwayama Y, Fukuo Y, Ikeda M, Okochi T, Maekawa M, et al. A
population-specific uncommon variant in GRIN3A associated with
schizophrenia. Biol Psychiatry. 2013;73:532–9.
112. Shen YC, Liao DL, Chen JY, Wang YC, Lai IC, Liou YJ, et al. Exomic
sequencing of the ionotropic glutamate receptor N-methyl-D-aspartate 3A
gene (GRIN3A) reveals no association with schizophrenia. Schizophr Res.
2009;114:25–32.
113. Diekstra FP, van Vught PW, van Rheenen W, Koppers M, Pasterkamp RJ, van
Es MA, et al. UNC13A is a modifier of survival in amyotrophic lateral
sclerosis. Neurobiol Aging. 2012;33:630.
114. van Es MA, Veldink JH, Saris CG, Blauw HM, van Vught PW, Birve A, et al.
Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as
susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;
41:1083–7.
115. Daoud H, Belzil V, Desjarlais A, Camu W, Dion PA, Rouleau GA. Analysis of
the UNC13A gene as a risk factor for sporadic amyotrophic lateral sclerosis.
Arch Neurol. 2010;67:516–7.
116. Koppers M, Groen EJ, Van Vught PW, Van Rheenen W, Witteveen E, Van Es
MA, et al. Screening for rare variants in the coding region of ALS-associated
genes at 9p21.2 and 19p13.3. Neurobiol Aging. 2013;34:1518 e5–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Oelsner et al. BMC Genomics  (2017) 18:57 Page 10 of 10
